DXCM — DexCom, Inc.

Summary of DexCom, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue was $1.19 billion, up 15% year-over-year (YoY) and 12% on an organic basis. U.S. revenue increased 11% to $832 million, while international revenue grew 26% to $360 million.
• Gross Profit: Gross profit was $757.4 million, representing a gross margin of 63.5%, up from 57.5% YoY.
• Operating Income: Operating income rose to $264.4 million (22.2% of revenue), compared to $143.1 million (13.8% of revenue) in Q1 2025.
• Net Income: Net income was $216.3 million, or $0.56 per share, reflecting a 75% increase YoY.
• Cash Position: The company ended the quarter with approximately $2.4 billion in cash and cash equivalents, up over $400 million from year-end 2025.

2. Strategic Updates and Business Highlights

• Product Launches: The DexCom G7 15-day system was launched successfully, receiving positive feedback for its accuracy and longer wear time. The company anticipates nearly 50% of its user base will switch to this product by year-end.
• Type 2 Diabetes Coverage: A significant reimbursement win was announced with Prime Therapeutics, expanding coverage to over 7 million type 2 non-insulin lives. This is expected to enhance market penetration and awareness.
• Clinical Evidence: The company is preparing to present results from a randomized control trial (RCT) at the ADA's 2026 Scientific Sessions, which aims to demonstrate the efficacy of CGM for type 2 non-insulin users.
• International Growth: Strong growth was reported in international markets, particularly in France and Canada, attributed to expanded access and tailored product offerings.

3. Forward Guidance and Outlook

• Revenue Guidance: The company reaffirmed its full-year revenue guidance of $5.16 billion to $5.20 billion, indicating growth of 11% to 13%.
• Margin Guidance: Gross profit margin guidance remains at 63% to 64%. Operating profit margin guidance was increased to 23% to 23.5%, and adjusted EBITDA margin guidance was raised to 31% to 31.5%.
• Market Dynamics: The company expects continued growth driven by new product launches and expanding coverage, particularly for type 2 diabetes.

4. Bad News, Challenges, or Points of Concern

• Market Growth Concerns: There are indications of slower growth in the U.S. CGM market, with some analysts questioning the sustainability of growth rates without significant new coverage expansions.
• Geopolitical Risks: The company has left gross margin guidance unchanged due to uncertainties related to fuel prices and shipping routes, which could impact future margins.
• Competition: The competitive landscape remains challenging, with peers noting similar market dynamics and potential slowdowns.

5. Notable Q&A Insights

• Market Penetration: CEO Jacob Leach emphasized that only 30% of covered lives are currently using CGM, indicating significant growth potential.
• Type 2 Non-Insulin Market: The company is focused on unlocking coverage for the type 2 non-insulin population, viewing it as a critical growth driver. Leach expressed confidence that CMS coverage for this group is a matter of time.
• Sales Strategy: The salesforce is being adapted to target primary care physicians more effectively, given the growing importance of this demographic in prescribing CGM.
• Retention and Utilization: The company is focused on improving customer satisfaction and retention metrics, which are crucial for sustaining growth.

Overall, DexCom's Q1 2026 performance reflects strong revenue growth and operational improvements, but the company faces challenges related to market dynamics and geopolitical risks. The strategic focus on expanding coverage and enhancing product offerings positions it well for future growth.